Bibliography
- MCKAY C, CURRAN FJ, SHARPLES CE et al: The use of lexipafant in the treatment of acute pancreatitis. Adv. Exp. Med. Biol. (1996) 416:365–370.
- Scrip (1998) 2308:22.
- Scrip (1997) 2293:12.
- TAMURA G, TAKISHIMA T, MUE S et al.: Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo- controlled study in Japan. Adv. Exp. Med. Biol. (1996) 416:371–380.
- Scrip (1997) 2255:12.
- MERLOS M, GIRAL M, BALSA D et al.: Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol Exp. Ther. (1997) 280:114–121.
- Drugs Future (1997) 22(10: 1296.
- Drugs Future (1997) 22(10:1299–1300.
- AYSCOUGH A, WHITTAKER M: Platelet-activating factor antagonists. Exp. Opin. Ther. Patents (1995) 5(7):653–672.
- SUMMERS JB, ALBERT DH: Platelet activating factor an-tagonists. Adv. Pharmacol (1995) 32:67–168.
- ••Comprehensive review of PAF antagonists of all structuraltypes along with a thorough discussion of antagonists in models of human disease including asthma and septic shock.
- SUMMERS JB, DAVIDSEN SK, SHEPPARD GS: Platelet activating factor antagonists. Curr. Pharm. Design (1995) 1:161–190.
- ••Comprehensive review of PAF antagonists with a detaileddiscussion of the structure-based drug design that has been utilised in this field.
- FROON AM, GREVE JW, BUURMAN WA et al: Treatmentwith the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory re-sponse syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock (1996) 5 (5) :313–319.
- BURES MG, DANAHER E, DELAZZER J et al.: New molecu-lar modeling tools using three-dimensional chemical substructures. J. Chem. Inf. Comp. Sci. (1994) 34:218–223.
- •General discussion of a number of structurally-related PAF antagonists and a pharmacophore model that explains their activity.
- HOLMS JH, DAVIDSEN SK, SHEPPARD GS et al: Discovery and optimisation of indole pyrrolothiazole PAF an-tagonists. Bioorg. Med. Chem. Letters (1995) 5:2903–2908.
- ALBERT DH, MAGOC TJ, KLEINERT HD et al: Ex vivo in-hibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist. Adv. Exp. Med. Biol. (1996) 416:381–387.
- CURTIN ML, DAVIDSEN SK, HEYMAN HR et al.: Discovery and evaluation of a series of 3-acylindole imidazopyri-dine platelet-activating factor antagonists. J. Med. Chem. (1998) 41:74–95.
- •An extensive summary of the chemical synthesis and bio-logical data associated with this series of antagonists.
- ALBERT DH, MAGOC TJ, TAPANG P et al.: Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist. Eur. J. Pharm. (1997) 325:69–80.
- ALBERT DH, MALO PE, TAPANG P et al.: The role ofplatelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J. Pharmacol. Exp. Ther. (1998) 284(1):83–88.
- CARCELLER E, MERLOS M, GIRAL M et al.: Design, synthesis, and structure-activity relationship studies ofnovel1-R1 -acy1-4-piperidy0methyll-1H-2-methylimidazo [4, 5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. J. Med. Chem. (1996) 39:487–493.
- KUWAHARA M, KAWANO Y, KAWAI T et al.: Synthetic studies on condensed-azole derivatives. I. Synthesis and anti-asthmatic activities of omega-substituted al-kylthioimidazo[1,2-b]pyridazines. Chem. Pharm. (1995) 43:1505–1510.
- Scrip (1997) 2235/6:26.
- LIU XH, EUN BL, SILVERSTEIN FS et al.: The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat. Pe-diatr. Res. (1996) 40:797–803.
- RODRIGUEZ-BARBERO A, LOPEZ-NOVOA JM, AREVALO M: Involvement of platelet-activating factor in genta-micin nephrotoxicity in rats. Exp. Nephrol. (1997) 5:47–
- SUGANO M, SATO A, IIJIMA Y et al.: Phomactins, novel PAF antagonists from marine fungus Phomas sp. J. Org. Chem. (1994) 59:564–569.
- SUGANO M, SATO A, SAITO K et al: Structure-activity re-lationships of phomactin derivatives as platelet acti-vating factor antagonists. J. Med. Chem. (1996) 39:5281–5284.